FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Akums Drugs will undertake this development and commercialization in India
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
Subscribe To Our Newsletter & Stay Updated